Dmitry Gabrilovich: Difference between revisions

From WikiMD's Wellness Encyclopedia

Newer edit →
CSV import
 
CSV import
Line 1: Line 1:
{{Orphan|date=March 2014}}
 
{{Infobox person
{{Infobox scientist
| image        = File:
| name = Dmitry Gabrilovich
| caption      = Gabrilovich in the lab
| image = <!-- Image removed -->
| name        = Dmitry Gabrilovich
| image_size = <!-- Image size removed -->
| birth_date   = {{birth date and age|mf=yes|1961|5|24}}
| alt = <!-- Alt text removed -->
| birth_place  = [[Minsk, USSR]]
| caption = <!-- Caption removed -->
| occupation  = Researcher, professor
| birth_date = <!-- Birth date removed -->
| years_active = 1984&ndash;present
| birth_place = <!-- Birth place removed -->
| nationality = <!-- Nationality removed -->
| fields = [[Immunology]], [[Cancer Research]]
| workplaces = [[Wistar Institute]]
| alma_mater = <!-- Alma mater removed -->
| known_for = Research on [[Myeloid-derived suppressor cells]]
| awards = <!-- Awards removed -->
}}
}}
'''Dmitry Gabrilovich, M.D., Ph.D.,''' is a researcher and Christopher M. Davis professor at [[The Wistar Institute]] in [[Philadelphia]].<ref>{{cite web|title=Dmitry I. Gabrilovich, M.D., Ph.D.|url=http://www.wistar.org/our-science/scientists/dmitry-gabrilovich-md-phd|publisher=[[The Wistar Institute]]|accessdate=17 February 2014}}</ref><ref>{{cite web|title=Prof Dmitry Gabrilovich|url=http://www.cvi.org.uk/speaker/prof-dmitry-gabrilovich/|publisher=[[Cancer Vaccine Institute]]|accessdate=17 February 2014}}</ref> His laboratory at Wistar focuses on methods by which [[tumors]] are able to suppress the immune system and how to develop new immune therapies to combat this ability.


The Gabrilovich lab focuses on immature [[myeloid]] cell biology and its relation to cancer. These cells have been linked to a number of signaling pathways associated with cancer, including NF-κB, Jak-STAT, Notch, Wnt, and Rb, among others.<ref>{{cite web|title=Dmitry I. Gabrilovich, M.D., Ph.D.|url=http://www.wistar.org/our-science/scientists/dmitry-gabrilovich-md-phd|publisher=The Wistar Institute|accessdate=17 February 2014}}</ref><ref>{{cite web|title=Speaker Biography: Dmitry Gabrilovich|url=http://www.immunopharmacology.elsevier.com/bio_gabrilovich.asp|publisher=[[Immunopharmacology]]|accessdate=17 February 2014}}</ref> His research has found that tumor cells can go through a mechanism that produces a free radical peroxynitrite, causing them to become resistant to certain types of cancer immunotherapy.<ref>{{cite web|title=Impediment to some cancer immunotherapy involves the free radical peroxynitrite|url=https://www.sciencedaily.com/releases/2011/09/110930195137.htm|publisher=[[Science Daily]]|accessdate=17 February 2014}}</ref> His research has also focused on monocytic-myeloid derived suppressor cells and polymorphonuclear-myeloid derived suppressor cells and what impact they might have on cancer therapy, since myeloid derived suppressor cells negatively regulate anti-tumor activity.<ref>{{cite web|title=Cancer-specific myelopoiesis|url=http://www.natureasia.com/en/research/highlight/2049|publisher=[[Nature Asia]]|accessdate=17 February 2014}}</ref>
'''Dmitry Gabrilovich''' is a prominent scientist known for his pioneering work in the field of [[immunology]] and [[cancer research]]. He is particularly recognized for his research on [[myeloid-derived suppressor cells]] (MDSCs), which play a crucial role in the [[tumor microenvironment]] and [[immune evasion]] by [[cancer]] cells.
 
== Education and Career ==
Dmitry Gabrilovich received his education in [[medicine]] and [[biomedical research]], focusing on the mechanisms of [[immune suppression]] in cancer. He has held various academic and research positions, contributing significantly to the understanding of how [[tumors]] evade the [[immune system]].
 
Currently, he is affiliated with the [[Wistar Institute]], where he leads a research team dedicated to exploring the interactions between the [[immune system]] and [[cancer]]. His work has been instrumental in developing new strategies for [[cancer immunotherapy]].


Prior to joining The Wistar Institute, Gabrilovich was a senior member at the [[Moffitt Cancer Center]] in [[Tampa]].<ref>{{cite web|title=Speaker Biography: Dmitry Gabrilovich|url=http://www.immunopharmacology.elsevier.com/bio_gabrilovich.asp|publisher=[[Immunopharmacology]]|accessdate=17 February 2014}}</ref>
== Research Contributions ==
Gabrilovich's research has shed light on the role of [[myeloid-derived suppressor cells]] in cancer progression. These cells are known to accumulate in [[cancer patients]] and suppress [[T cell]] responses, thereby facilitating [[tumor growth]] and [[metastasis]].


==Select publications==
His studies have demonstrated that targeting MDSCs can enhance the efficacy of [[immunotherapeutic]] approaches, making them a promising target for [[cancer treatment]].
* Condamine T, Ramachandran I, Youn JI, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med. 2015 Jan 14;66:97-110.
* Nagaraj S, Youn JI, Gabrilovich DI. Reciprocal Relationship between Myeloid-Derived Suppressor Cells and T Cells. J Immunol. 2013 Jul 1;191(1):17-23.
* Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013 Oct;13(10):739-52.
* Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013 Mar;14(3):211-20.
* Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014 Jun 2;124(6):2626-39


==References==
== Publications and Awards ==
{{reflist}}
Dmitry Gabrilovich has published numerous articles in prestigious [[scientific journals]], contributing to the body of knowledge in [[immunology]] and [[oncology]]. His work has been recognized with several awards, highlighting his impact on the field of [[cancer research]].


==External links==
== See Also ==
*[http://www.wistar.org/lab/dmitry-gabrilovich-md-phd Dr. Gabrilovich's lab page on The Wistar Institute's website]
* [[Immunotherapy]]
* [[Tumor microenvironment]]
* [[Cancer immunology]]


{{DEFAULTSORT:Gabrilovich, Dmitry}}
== References ==
<references />
 
== External Links ==
* [Wistar Institute Profile](https://www.wistar.org/our-scientists/dmitry-gabrilovich)
 
[[Category:Immunologists]]
[[Category:Cancer researchers]]
[[Category:Cancer researchers]]
[[Category:Living people]]
[[Category:Living people]]
[[Category:1954 births]]
[[Category:Wistar Institute faculty]]
 
 
{{US-med-bio-stub}}
{{oncology-stub}}
{{dictionary-stub1}}

Revision as of 04:35, 29 December 2024


Dmitry Gabrilovich







Known forResearch on Myeloid-derived suppressor cells


Dmitry Gabrilovich is a prominent scientist known for his pioneering work in the field of immunology and cancer research. He is particularly recognized for his research on myeloid-derived suppressor cells (MDSCs), which play a crucial role in the tumor microenvironment and immune evasion by cancer cells.

Education and Career

Dmitry Gabrilovich received his education in medicine and biomedical research, focusing on the mechanisms of immune suppression in cancer. He has held various academic and research positions, contributing significantly to the understanding of how tumors evade the immune system.

Currently, he is affiliated with the Wistar Institute, where he leads a research team dedicated to exploring the interactions between the immune system and cancer. His work has been instrumental in developing new strategies for cancer immunotherapy.

Research Contributions

Gabrilovich's research has shed light on the role of myeloid-derived suppressor cells in cancer progression. These cells are known to accumulate in cancer patients and suppress T cell responses, thereby facilitating tumor growth and metastasis.

His studies have demonstrated that targeting MDSCs can enhance the efficacy of immunotherapeutic approaches, making them a promising target for cancer treatment.

Publications and Awards

Dmitry Gabrilovich has published numerous articles in prestigious scientific journals, contributing to the body of knowledge in immunology and oncology. His work has been recognized with several awards, highlighting his impact on the field of cancer research.

See Also

References

<references />

External Links

Retrieved from "https://wikimd.com/index.php?title=Dmitry_Gabrilovich&oldid=6080632"